As of 2024-12-11, the Relative Valuation of Urogen Pharma Ltd (URGN) is (24.33) USD. This relative valuation is based on P/E multiples. With the latest stock price at 12.04 USD, the upside of Urogen Pharma Ltd based on Relative Valuation is -302.1%.
The range of the Relative Valuation is (10.99) - (36.69) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 3.9x - 13.4x | 8.6x |
| Forward P/E multiples | 4.0x - 14.3x | 9.2x |
| Fair Price | (10.99) - (36.69) | (24.33) |
| Upside | -191.3% - -404.7% | -302.1% |
| Date | P/E |
| 2024-12-09 | -4.45 |
| 2024-12-06 | -4.50 |
| 2024-12-05 | -4.47 |
| 2024-12-04 | -4.56 |
| 2024-12-03 | -4.51 |
| 2024-12-02 | -4.71 |
| 2024-11-29 | -4.65 |
| 2024-11-27 | -4.63 |
| 2024-11-26 | -4.56 |
| 2024-11-25 | -4.56 |
| 2024-11-22 | -4.36 |
| 2024-11-21 | -4.22 |
| 2024-11-20 | -4.19 |
| 2024-11-19 | -4.08 |
| 2024-11-18 | -4.04 |
| 2024-11-15 | -4.09 |
| 2024-11-14 | -4.34 |
| 2024-11-13 | -4.45 |
| 2024-11-12 | -4.52 |
| 2024-11-11 | -4.68 |
| 2024-11-08 | -4.43 |
| 2024-11-07 | -4.43 |
| 2024-11-06 | -4.48 |
| 2024-11-05 | -4.47 |
| 2024-11-04 | -4.36 |
| 2024-11-01 | -4.46 |
| 2024-10-31 | -4.48 |
| 2024-10-30 | -4.76 |
| 2024-10-29 | -4.48 |
| 2024-10-28 | -4.44 |
| 2024-10-25 | -4.43 |
| 2024-10-24 | -4.43 |
| 2024-10-23 | -4.44 |
| 2024-10-22 | -4.56 |
| 2024-10-21 | -4.58 |
| 2024-10-18 | -4.66 |
| 2024-10-17 | -4.70 |
| 2024-10-16 | -4.61 |
| 2024-10-15 | -4.48 |
| 2024-10-14 | -4.48 |
| 2024-10-11 | -4.61 |
| 2024-10-10 | -4.36 |
| 2024-10-09 | -4.35 |
| 2024-10-08 | -4.80 |
| 2024-10-07 | -4.54 |
| 2024-10-04 | -4.65 |
| 2024-10-03 | -4.53 |
| 2024-10-02 | -4.60 |
| 2024-10-01 | -4.56 |
| 2024-09-30 | -4.65 |